July 17, 2026 · PDUFA decision
CELC PDUFA decision: a positive outcome, +7.0%
On July 17, 2026, Gedatolisib — Celcuity Inc. (CELC) (mCRPC (Metastatic Castration-resistant Prostate Cancer)) reached its PDUFA decision. The result was a positive outcome, and the stock moved +7.0% in the window around the event. It had already run +21.5% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$103.79
1d before
$111.05
Event day
$91.51
1d after
$88.38
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (+0.0% expected); the stock actually moved +7.0%. Model confidence at the time: 35%.
See the full scored track recordPre-catalyst setup
+21.5%
30-day run-up
5469%
30-day volatility
1.0×
volume spike